{
    "Rank": 754,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT04980989",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "112/13/03/02/2015"
                },
                "Organization": {
                    "OrgFullName": "Helsinki University Central Hospital",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software",
                "OfficialTitle": "A Prospective Randomized Trial of Interactive Telemonitoring in the Follow-up of Patients Treated for Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "July 2021",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "June 15, 2015",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "June 15, 2021",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "June 15, 2021",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "July 21, 2021",
                "StudyFirstSubmitQCDate": "July 21, 2021",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "July 28, 2021",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "July 21, 2021",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "July 28, 2021",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Johanna Mattson",
                    "ResponsiblePartyInvestigatorTitle": "Physician-in-Chief",
                    "ResponsiblePartyInvestigatorAffiliation": "Helsinki University Central Hospital"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Helsinki University Central Hospital",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "University of Helsinki",
                            "CollaboratorClass": "OTHER"
                        },
                        {
                            "CollaboratorName": "Noona Healthcare",
                            "CollaboratorClass": "UNKNOWN"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference which was the primary end-point. At baseline, 6 months and 12 months the patients answered the other questionnaires.",
                "DetailedDescription": "Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm.\n\nThe primary end point was to find out patient preference for the modality of surveillance. Secondary endpoints were patient satisfaction, symptoms, quality of life and cost of follow-up during surveillance modalities.\n\nAt 12 months the patients were asked their preference for the follow-up modality of early breast cancer. At baseline, 6 months and 12 months the patients answered the other questionnaires on quality of life, symptoms, patient satisfaction and use of other health-care services. Information on the cost of follow-up was gathered from the hospital and other registries."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer, Early-Onset"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "follow-up, mobile software, early breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Not Applicable"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "Randomized",
                    "DesignInterventionModel": "Crossover Assignment",
                    "DesignInterventionModelDescription": "Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference. At baseline, 6 months and 12 months the patients answered the other questionnaires on patient satisfaction, quality of life, symptoms and use of other healthcare services.",
                    "DesignPrimaryPurpose": "Health Services Research",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "765",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Mobile software",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Patient with early breast cancer were followed-up by mobile software for the first six months. At six months they crossed-over to be followed-up by telephone calls for the next six months.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Device: Mobile software for follow-up of early breast cancer"
                                ]
                            }
                        },
                        {
                            "ArmGroupLabel": "Telephone calls",
                            "ArmGroupType": "Active Comparator",
                            "ArmGroupDescription": "Patient with early breast cancer were followed-up by telephone calls for the first six months. At six months they crossed-over to be followed-up by mobile software for the next six months.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Device: Mobile software for follow-up of early breast cancer"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Device",
                            "InterventionName": "Mobile software for follow-up of early breast cancer",
                            "InterventionDescription": "The patients were randomized to use mobile software or telephone calls as the follow-up modality for early breast cancer",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Mobile software",
                                    "Telephone calls"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Noona mobile software"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Patient preference for follow-up modality",
                            "PrimaryOutcomeDescription": "Questionnaire of patient preference",
                            "PrimaryOutcomeTimeFrame": "At 12 months during follow-up of early breast cancer"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Quality of life during follow-up modality",
                            "SecondaryOutcomeDescription": "Quality of life questionnaires",
                            "SecondaryOutcomeTimeFrame": "At baseline, 6 months and 12 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Patient satisfaction",
                            "SecondaryOutcomeDescription": "Patient satisfaction questionnaires",
                            "SecondaryOutcomeTimeFrame": "At 6 months and 12 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Symptoms",
                            "SecondaryOutcomeDescription": "Symptom questionnaire",
                            "SecondaryOutcomeTimeFrame": "At baseline, 6 months and 12 months"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Use of other healthcare services",
                            "SecondaryOutcomeDescription": "Questionnaire",
                            "SecondaryOutcomeTimeFrame": "At 6 months and 12 months"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nAdult patients with early breast cancer after primary treatment including also radiotherapy (the patients were randomized at the final visit of radiotherapy)\n\nExclusion Criteria:\n\nnot able to use a computer\nanother malignancy",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Johanna Mattson, MD, PhD",
                            "OverallOfficialAffiliation": "Helsinki University Central Hospital",
                            "OverallOfficialRole": "Principal Investigator"
                        },
                        {
                            "OverallOfficialName": "Carl Blomqvist, Professor",
                            "OverallOfficialAffiliation": "Helsinki University Central Hospital",
                            "OverallOfficialRole": "Study Chair"
                        },
                        {
                            "OverallOfficialName": "Johanna Mattson, MD, PhD",
                            "OverallOfficialAffiliation": "Helsinki University Central Hospital",
                            "OverallOfficialRole": "Study Director"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}